TrialNeuro-oncology2021

MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.

Didier Frappaz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.